Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

French-born Weber oversaw a reorientation that included the $62 billion acquisition of British rival Shire in 2019.

US President Donald Trump has warned BRICS nations against introducing a new currency or backing an alternative to the U.S.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...